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Fondaparinux Superior to Enoxaparin in ACS Patients Undergoing PCI
TheOASIS-5 trial demonstrated that the factorXa inhibitor fondaparinux reducedmajor bleeding and improved 30-day mortality compared with enoxaparin in
acute coronary syndrome (ACS)patients.This substudy compares the2medications in
patients who underwent percutaneous coronary intervention (PCI) during the initial
hospitalization. Fondaparinux was associated with a50% reduction in major bleed-
ing, with similar rates of ischemic events. However, there were rare cases of catheter-
associated thrombosis when fondaparinux was used without unfractionated heparin
during PCI. These data demonstrate that, in the context of an early invasive strategy,
fondaparinux appears safer than enoxaparin, with the caveat that unfractionated
heparin rather than intravenous fondaparinux be used as adjunctive therapy at the time
of PCI. See page 1742.
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Myocardial Infarction
Long-Term Mortality After Cardiogenic Shock
Although cardiogenic shock is known to portend a high rate of early mortalityfollowing ST-segment elevation myocardial infarction (STEMI), less is known
about the long-term effect on mortality. Singh and colleagues queried the Social
Security database for patients enrolled in the GUSTO-I trial. In that trial, shock
occurred in 8%of patients, 50%ofwhomdiedwithin the first 30days. After excluding
deaths within the first year, 2% to 4% of patients died each year, regardless of whether
they experienced cardiogenic shock or not. The early mortality rate of STEMI com-
plicated by cardiogenic shock is very high; however, thosewho survive for at least 1 year
have similar survival rates as those who do not develop shock. See page 1752. See
figure.
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Myocardial Infarction
Meta-Analysis of Cellular Therapy for AMI
Theintracoronary injection of either bonemarrow cells or peripheralmononuclearcells is postulated to improve cardiac functional recovery after acute myocardial
infarction (AMI), but the results of clinical studies have not been conclusive. Lipinksi
and colleagues performed ameta-analysis of studies that randomized patients to either
cellular injections or placebo within 14 days of AMI. There were 10 trials with almost
700 patients. Cellular therapy was associated with a modest but statistically significant
increase in left ventricular ejection fraction of 3%, along with trends toward reduced
death, re-hospitalization for heart failure, and repeat revascularization. This analysis of
patients that received intracoronary cell therapy after AMI suggests statistically and
clinically relevant benefits on cardiac function and remodeling. See page 1761.
See figure.
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Coronary Artery Disease
Novel Biomarker Links Inflammation, Platelet Adhesion, and CAD
TheF11 receptor (F11R) is expressedbybothplatelets and endothelial cells andhasrecently been demonstrated to foster platelet adhesion to cytokine-inflamed
endothelial surfaces. Cavusoglu and colleagues developed an enzyme-linked immuno-
sorbent assay for soluble F11R, which was then measured in nearly 400 patients
undergoing angiography. Plasma F11R levels were independently associated with the
presence and severity of coronary artery disease (CAD). These findings suggest that
F11R may be an important mediator of the effects of inflammation on the vessel wall
andmay be a useful biomarker for grading cardiovascular risk.See page 1768. See
figure.
